Non-small Cell Lung Cancer (PD-L1 Expression): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 72-year-old Caucasian male, who is a former smoker with a history of hypertension, diabetes, and BPH. He has NSCLC adenocarcinoma histology and is positive for the KRAS mutation G12C.

Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity. 

Learning Objectives

  • Evaluate the data for immune checkpoint inhibitors as second line therapy in patients with advanced NSCLC
  • Discuss the differences in efficacy based on PD-L1 status and smoking history 
  • Analyze the different antibodies and cut points being explored and how this applies to current practice 

Competencies Addressed

Medical Knowledge (ACGME, AAPA)

Health Promotion, Health Protection, Disease Prevention, and Treatment (ONS)